anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A therapeutic agent for antidiabetes is provided to effectively prevent and treat type I diabetes and suppress the damage of islet after pancreas surgery. A therapeutic agent for treating a type I diabetes comprises a Fructus xanthii extract. The therapeutic agent for suppressing the damage of islet after pancreas surgery or pancreatic duct transplantation surgery comprises the Fructus xanthii extract. The Fructus xanthii extract contains Fructus xanthii and water in a weight ratio of 1:3-9, and is obtained by extracting at 5-100C for 15 minutes - 48 hours. A pharmaceutical composition for preventing and treating antidiabetes comprises 0.1-99 weight% of Fructus xanthii, carrier, excipient, and diluents. The composition is formulated in a type of power, tablet, capsule, suspension, syrup, oral formulation selected from pill or aerosol, suppository, or the sterilization injection agent.
This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis.Duration of treatment is 12 week in total. Study visits will occur every 4 weeks. During these visits study drug will be administered at the site, new AEs/SAEs as well as follow-up for AEs and SAEs that have not been resolved will be recorded, changes to concomitant medications will be noted, vital signs will be taken, and efficacy evaluations will be performed as well. The study includes collection of cytokines samples. The end-of-treatment visit and the last estimation of variable scores will occur at week 13 (visit 5) for all subjects. The final visit will be at week 15 (visit 6). Subjects will be encouraged to complete all planned visits regardless of their adherence to study drug administration.
The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension.

Because metoclopramide produces a transient increase in plasma aldosterone, certain patients, especially those with cirrhosis or congestive heart failure, may be at risk of developing fluid retention and volume overload. If these side effects occur at anytime during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of metoclopramide. A small number of patients may experience a withdrawal period after stopping metoclopramide that could cause dizziness, nervousness, and/or headaches.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
PURPOSE:To remove selectively the cholesterol in blood by a vinyl polymer having the arom. nucleus into which the functional group expressed by the specific formula is incorporated as a side chain and the molding thereof. CONSTITUTION:A vinyl polymer having the arom. nucleus into which the functional group expressed by the formula is incorporated as a side chain and the molding thereof constitute a blood treating agent. The result is much better if the polymer is crosslinked and if the polymer is reinforced by poly alpha-olefin as represented by crystalline PP or PE as the mechanical strength is improved with the latter. The immobilizing density decreases if the surface area is too small in the case of the molding but if the surface area is too large, the liquid passability of the column in which the molding is packed decreases and therefore the preferable surface area is 0.01-50m<2>/g.
Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
Renal transplantation is common worldwide, with >25,000 procedures performed in 2022. Usage of prophylactic perinephric drains is variable in renal transplantation; drains are associated with risks, and there is a lack of consensus regarding benefit of routine drain placement in these patients. This meta-analysis assessed whether prophylactic drainage reduced need for reintervention postoperatively. This systematic review and meta-analysis was carried out using the Preferred Reporting Items in Systematic Reviews and Meta-Analysis, and prospectively registered on PROSPERO. Summary statistics for outcomes of interest underwent meta-analyses to a confidence interval (CI) of 95% and are presented as Forest Plots for Odds Ratio (OR). A systematic literature search in June 2023 revealed 1,540 unique articles across four databases. Of these, four retrospective cohort studies were selected. Meta-analysis of three studies showed no significant reduction in reintervention rate with pre-emptive drain placement, OR = 0.59 (95% CI: 0.16-2.23), p = 0.44. Meta-analysis did not show a significant reduction in perinephric collections with prophylactic drain insertion OR = 0.55 (95% CI: 0.13-2.37), p = 0.42. Finally, there is not good evidence that drain placement reduces superficial wound complications or improves 12-month graft survival. Further work is needed, including well-designed, prospective studies to assess the risks and benefits of drain placement in these patients. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023422685, Identifier PROSPERO CRD42021255795.
Neutrophil extracellular traps (NETs), crucial in immune defense mechanisms, are renowned for their propensity to expel decondensed chromatin embedded with inflammatory proteins. Our comprehension of NETs in pathogen clearance, immune regulation and disease pathogenesis, has grown significantly in recent years. NETs are not only pivotal in the context of infections but also exhibit significant involvement in sterile inflammation. Evidence suggests that excessive accumulation of NETs can result in vessel occlusion, tissue damage, and prolonged inflammatory responses, thereby contributing to the progression and exacerbation of various pathological states. Nevertheless, NETs exhibit dual functionalities in certain pathological contexts. While NETs may act as autoantigens, aggregated NET complexes can function as inflammatory mediators by degrading proinflammatory cytokines and chemokines. The delineation of molecules and signaling pathways governing NET formation aids in refining our appreciation of NETs' role in immune homeostasis, inflammation, autoimmune diseases, metabolic dysregulation, and cancer. In this comprehensive review, we delve into the multifaceted roles of NETs in both homeostasis and disease, whilst discussing their potential as therapeutic targets. Our aim is to enhance the understanding of the intricate functions of NETs across the spectrum from physiology to pathology.
Steady-state visual evoked potential (SSVEP)-based brain-computer interfaces (BCIs) have emerged as a prominent technology due to their high information transfer rate, rapid calibration time, and robust signal-to-noise ratio. However, a critical challenge for practical applications is performance degradation caused by user fatigue during prolonged use. This work proposes novel methods to address this challenge by dynamically adjusting data acquisition length and updating detection models based on a fatigue-aware stopping strategy. Two 16-target SSVEP-BCIs were employed, one using low-frequency and the other using high-frequency stimulation. A self-recorded fatigue dataset from 24 subjects was utilized for extensive evaluation. A simulated online experiment demonstrated that the proposed methods outperform the conventional fixed stopping strategy in terms of classification accuracy, information transfer rate, and selection time, irrespective of stimulation frequency. These findings suggest that the proposed approach can significantly improve SSVEP-BCI performance under fatigue conditions, leading to superior performance during extended use.
The Sponsor is developing the test medicine, Capivasertib, for the potential treatment of primary breast and prostate cancer. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably, causing a growth called a tumour. The cancerous cells can invade and destroy surrounding healthy tissue, including organs. The four most common types of cancer within the UK are: breast, lung, prostate and bowel cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the blood stream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine. Two out of three recipes of the test medicine are radiolabelled with carbon-14. 'Radiolabelled' means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body. This study will consist of two periods involving up to eight healthy male volunteers aged 30-65 and will take place at one non-NHS site. In Part 1, volunteers will receive a single dose of 2 non-radiolabelled oral tablets in the fasted state followed by an intravenous infusion (solution into the vein) of radiolabelled test medicine 1 hour 15 mins minutes later. Volunteers will be discharged from the clinical unit on Day 5. In Part 2, volunteers will receive a single oral dose of a radiolabelled oral solution in the fasted state. Volunteers will be discharged on Day 8, however may be required to remain at the clinical unit until Day 10 if the mass balance criteria have not been met by Day 8. Volunteers will receive a follow up phone call between Day 15 and Day 19. Volunteer's blood, urine and faeces will be taken throughout the study for analysis of the test medicine, radiation and for safety. Volunteers are expected to be involved in this study for approximately 9 weeks from screening to the follow-up call.
Methods Five hundred and four navigated total knee arthroplasties will be analyzed. The following angles will be measured with a computer image free navigation system: medial femorotibial mechanical angle without stress and with maximum manual stress to reduce deformation, and medial distal femoral mechanical angle. The native medial distal femoral and medial proximal tibial angles will be calculated. The data will be analyzed as numerical and categorical data. These data will be then compared with those published in a non-arthritic population, considered as a control group.

The main criterion will be the percentage of subjects with normal overall coronal alignment, defined by the association of a normal native medial distal femoral angle and a normal native medial proximal tibial angle. The secondary criteria will be the percentages of subjects with normal medial femorotibial mechanical angle, normal native medial distal femoral angle and normal native medial proximal tibial angle. The influence of gender on primary and secondary criteria in the study group will be analyzed. The most frequent phenotypes in the study group will be identified.
Atrial fibrillation (AFib) is the most common cardiac rhythm disturbance, often treated via electrical cardioversion. Following rhythm restoration, a period of depressed mechanical function known as atrial stunning occurs, suggesting that defects in contractility occur in AFib and are revealed upon restoration of rhythm. This project aims to define the contractile remodeling that occurs in AFib. To assess contractile function, we used a canine atrial tachypacing model of induced AFib. Mass spectrometry analysis showed dysregulation of contractile proteins in samples from AFib compared with sinus rhythm atria. Atrial cardiomyocytes show reduced force of contraction, decreased resting tension, and increased calcium sensitivity in skinned single cardiomyocyte studies. These alterations correlated with degradation of myofilament proteins including myosin heavy chain altering force of contraction, titin altering resting tension, and troponin I altering calcium sensitivity. We measured degradation of other myofilament proteins, including cardiac myosin binding protein C and actinin, that show degradation products in the AFib samples that are absent in the sinus rhythm atria. Many of the degradation products appeared as discrete cleavage products that are generated by calpain proteolysis. We assessed calpain activity and found it to be significantly increased. These results provide an understanding of the contractile remodeling that occurs in AFib and provide insight into the molecular explanation for atrial stunning and the increased risk of atrial thrombus and stroke in AFib.NEW & NOTEWORTHY Atrial fibrillation is the most common cardiac rhythm disorder, and remodeling during atrial fibrillation is highly variable between patients. This study has defined the biophysical changes in contractility that occur in atrial fibrillation along with identifying potential molecular mechanisms that may drive this remodeling. This includes proteolysis of several myofilament proteins including titin, troponin I, myosin heavy chain, myosin binding protein C, and actinin, which is consistent with the observed contractile deficits.
Same as for period 1, but with a blinded sensor (FreeStyle Libre Pro). The data from the blinded sensors are concealed from both participants and nurses and will be used for comparison with the experimental arm.
A health monitoring device is provided, and may be used in population health monitoring and disease tracing, as well as for individual subject health purposes. The health monitoring device comprises a triboelectric nanogenerator (TENG) for generating and storing electrical energy from mechanical activity of a user. The device provides a continuous and uninterrupted stream of physiological data received at a surface of the device in contact with a surface of the user. The triboelectric nanogenerator is a paper-based device comprising a paper-based material layer and a polydimethylsiloxane/polytetrafluoroethylene (PDMS/PTFE) material layer, each on a copper film. The device has enhanced sensitivity to motion, providing an improved device capable of converting small amounts of movement into electrical energy, and of recording and transmitting data of small physiological changes of a user to a receiver. The device is lithium free, and eliminates the necessity of recharging.
Acute Mania

Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq/L. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient’s clinical state and of serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.

Long-Term Control

The desirable serum lithium levels are 0.6 to 1.2 mEq/mL. Dosage will vary from one individual to another, but usually 300 mg of Lithium Carbonate t.i.d. or q.i.d., will maintain this level. Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.

Patients abnormally sensitive to lithium may exhibit toxic signs at serum levels of 1.0 to 1.5 mEq/mL. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.

N.B.

Blood samples for serum lithium determination should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8 to 12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.
PURPOSE: To provide a medicinal compsn. effective for medication into the inside of the vein or artery with lapamycin in order to treat the diseases, syndromes, symptoms or immunological response reacting with the treatment using the lapamycin and a process for producing the same. CONSTITUTION: This medicinal compsn. contains the lapamycin added tangible blood components suspended in the plasma or its physiological substitute and is produced by separating the tangible blood components of the mammals from another components, incubating these components together with the lapamycin and suspending the resulted lapamycin added tangible blood components in the plasma or its physiological substitute. The lapamycin which is the effective component is added to the tangible blood components and is, therefore, protected against the decomposition by metabolysis and the biological utilization rate thereof is high. Since an unnatural excipient is not used, there is no worry about the induction of anaphylactoid reaction.
Fluoxetine pharmacokinetics were evaluated in 21 pediatric patients (ten children ages 6 to < 13, 11 adolescents ages 13 to < 18) diagnosed with major depressive disorder or obsessive compulsive disorder (OCD). Fluoxetine 20 mg/day was administered for up to 62 days. The average steady-state concentrations of fluoxetine in these children were 2-fold higher than in adolescents (171 and 86 ng/mL, respectively). The average norfluoxetine steady-state concentrations in these children were 1.5-fold higher than in adolescents (195 and 113 ng/mL, respectively). These differences can be almost entirely explained by differences in weight. No gender-associated difference in fluoxetine pharmacokinetics was observed. Similar ranges of fluoxetine and norfluoxetine plasma concentrations were observed in another study in 94 pediatric patients (ages 8 to < 18) diagnosed with major depressive disorder. 

Higher average steady-state fluoxetine and norfluoxetine concentrations were observed in children relative to adults; however, these concentrations were within the range of concentrations observed in the adult population. As in adults, fluoxetine and norfluoxetine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3 to 4 weeks of daily dosing.
Children aged 3-5 years, enrolled in kindergartens. The pathfinder sampling technique has been used to obtain a representative sample. As suggested by the WHO, this survey design is suitable for collection of data for planning purposes and monitoring of oral health programmes in all countries regardless of the level of disease, availability of resources or complexity of care. Clinical examinations will be performed using ICDAS criteria by calibrated medical staff from each partner university. Caries incidence rate will be calculated on each tooth as the unit of analysis and evaluated using a multi-step approach: net increment for caries severity using ICDAS calculated at each follow-up examinations; Events defined as a new lesion or as the sum of the Δ-caries changes of status recorded at the baseline, at interim, and at the last examination. The number of events will be appraised by subtracting the number of caries-free teeth at last examination from those at baseline.
We report a nosocomial outbreak caused by a multidrug-resistant carbapenemase-producing Klebsiella pneumoniae (MDRCPKp), that was detected in six patients admitted to the medical intensive care unit between 20th of December 2023 and 15th of January 2024 in Ankara, Turkey. The investigation of this outbreak was started on 29th of December 2023. During the outbreak 11 samples were collected from the six patients with MDRCPKp. Pulsed-field gel electrophoresis (PFGE) was performed to determine the genetic relatedness and clonality of MDRCPKp strains. MDRCPKp was isolated in the tracheal aspiration culture, blood, urine, and screening samples. Five patients with MDRCPKp colonization developed healthcare-associated infection. In one patient MDRCPKp was isolated from tracheal aspirate and the screening cultures were considered as colonization not infection. PFGE analysis revealed that all isolates belonged to the same K. pneumoniae clone. MDRCPKp strain of this outbreak exhibited multidrug resistance and co-produced OXA-48 and NDM-1. This outbreak ended after application of strict infection control measures. An outbreak of MDRCPKp can occur in hospitals, especially in the intensive care units; thus, it should be detected early by infection control teams. A strong collaboration between infection control team and microbiology laboratory is essential to cope with MDR bacterial outbreaks in hospitals.
A kind of polysaccharide, which consists of glucose and glycuronic acid and does not comprise protein and nucleic acid, has molecular weight of 1.6x 106-2.6x 106Da, alpha-configuration end group carbon and optical rotation [α]Dt of +131.7 - +159.4°. The basic framework of the polysaccharide is consisted of glucose with 1→4 glycosidic linkage, and every 17 glucose residual groups there is a pendant chain of glucose molecule or glycuronic acid molecule, the ratio of glucose and glycuronic acid is 2:1, linking to the glucose in main chain with l→6 glycosidic linkage. In each mole polysaccharide the mole ratio of glucose and glycosidic acid is 53:1. The polysaccharide YCP in this invention can efficiently suppress the Heps and S180 mice-transplanted tumor. So the polysaccharide YCP in this invention can be used to prepare medicine curing tumor. It's preparation method is disclosed in this invention.
* Do not shake. Do not use PROCRIT that has been shaken or frozen.
  * Protect vials from light.
  * Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use any vials exhibiting particulate matter or discoloration.
  * Discard unused portions of PROCRIT in preservative-free vials. Do not re-enter preservative-free vials.
  * Store unused portions of PROCRIT in multidose vials at 36°F to 46°F (2°C to 8°C). Discard 21 days after initial entry.
  * Do not dilute. Do not mix with other drug solutions except for admixing as described below: 
    * Preservative-free PROCRIT from single-use vials may be admixed in a syringe with bacteriostatic 0.9% sodium chloride injection, USP, with benzyl alcohol 0.9% (bacteriostatic saline) in a 1:1 ratio using aseptic technique at the time of administration. Risks are associated with benzyl alcohol in neonates, infants, pregnant women, and nursing mothers [see Use in Specific Populations (8.1, 8.3, 8.4)].
1. Hemoglobin and hematocrit levels should be checked periodically (to detect polycythemia) in patients on long-term androgen therapy. 
  2. Liver function, prostate specific antigen (PSA), cholesterol and high-density lipoprotein should be checked periodically.
  3. Serum total testosterone concentrations may be checked four to twelve weeks after initiating treatment with Striant®. To capture the maximum serum concentration, an early morning sample (just prior to applying the A.M. dose) is recommended. In the infrequent circumstance where the total testosterone concentration in this sample is excessive, therapy with Striant® should be discontinued and an alternative treatment considered.
A film-forming composition. comprising: a blend of i) a polysiloxane comprising one or more hydroxyl groups: ii) a polymer comprising a nitrogen-containing repeating unit. wherein the nitrogen-containing repeating unit is an amide. tertiary amine. benzylic amine, or heterocyclic amine: iii) optionally. a solvent: wherein the film formed from the film-forming composition is water-disintegrable.